Related Experiment Video
Updated: Mar 30, 2026
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Hepatocyte-Specific Arid1a Deficiency Initiates Mouse Steatohepatitis and Hepatocellular Carcinoma
Jia-Zhu Fang1,2,3, Chong Li4, Xiao-Yan Liu1,2
1Key Laboratory of Systems Biomedicine (Ministry of Education) and Collaborative Innovation Center of Systems Biomedicine of Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Abstract:
ARID1A, encoding a subunit of chromatin remodeling SWI/SNF complexes, has recently been considered as a new type of tumor suppressor gene for its somatic mutations frequently found in various human tumors, including hepatocellular carcinoma (HCC). However, the role and mechanism of inactivated ARID1A mutations in tumorigenesis remain unclear. To investigate the role of ARID1A inactivation in HCC pathogenesis, we generated hepatocyte-specific Arid1a knockout (Arid1aLKO) mice by crossing mice carrying loxP-flanked Arid1a exon 8 alleles (Arid1af/f) with albumin promoter-Cre transgenic mice. Significantly, the hepatocyte-specific Arid1a deficiency results in mouse steatohepatitis and HCC development. In Arid1aLKO mice, we found that innate immune cells, including F4/80+ macrophages and CD11c+ neutrophil cells, infiltrate into the liver parenchyma, accompanied by the increased tumor necrosis factor (TNF)-α and interleukin (IL)-6, and activation of STAT3 and NF-κB pathways. In conclusion, hepatocyte-specific Arid1a deficiency could lead to mouse steatohepatitis and HCC development. This study provides an alternative mechanism by which Arid1a deficiency contributes to HCC tumorigenesis.
Insights
Hepatocyte-specific inactivation of ARID1A, a tumor suppressor gene, triggers mouse steatohepatitis and hepatocellular carcinoma (HCC). This occurs through innate immune cell infiltration and inflammatory pathway activation, revealing a novel mechanism in HCC development.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- ARID1A, a tumor suppressor gene, is frequently mutated in human cancers, including hepatocellular carcinoma (HCC).
- The precise role and mechanism of ARID1A inactivation in HCC pathogenesis are not fully understood.
Purpose of the Study:
- To investigate the role of ARID1A inactivation in HCC development.
- To elucidate the underlying mechanisms of ARID1A-deficient HCC.
Main Methods:
- Generation of hepatocyte-specific Arid1a knockout (Arid1aLKO) mice.
- Analysis of liver pathology, immune cell infiltration, and inflammatory markers in Arid1aLKO mice.
Main Results:
- Hepatocyte-specific Arid1a deficiency led to mouse steatohepatitis and HCC development.
- Infiltration of innate immune cells (macrophages, neutrophils) and increased levels of TNF-α and IL-6 were observed.
- Activation of STAT3 and NF-κB inflammatory pathways was detected in Arid1aLKO livers.
Conclusions:
- Hepatocyte-specific ARID1A deficiency promotes steatohepatitis and HCC development in mice.
- ARID1A inactivation contributes to HCC tumorigenesis via innate immune cell infiltration and inflammatory signaling.
